Biological response genes after single dose administration of interferon β-1b to healthy male volunteers

Journal of Neuroimmunology

Volumn 199, Issue 1-2, 2008, Pages 115-125

  Hilpert, Jan ^a   Beekman, Johanna M ^a   Schwenke, Susanne ^a   Kowal, Kristin ^a   Bauer, David ^a   Lampe, Johannes ^a   Sandbrink, Rupert ^a   Heubach, Jürgen F ^a   Stürzebecher, Steffen ^a   Reischl, Joachim ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Biomarker; Gene expression; Interferon beta; Metallothionein; MxA; Time course

Indexed keywords

INTERFERON BETA SERINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN EXPERIMENT; MALE; MICROARRAY ANALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADJUVANTS, IMMUNOLOGIC; ADULT; DOUBLE-BLIND METHOD; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 47549110924     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.04.036     Document Type: Article

References (46)

1. Aebi M., Fäh J., Hurt N., Samuel C.E., Thomis D., Bazzigher L., Pavlovic J., Haller O., and Staeheli P. cDNA structures and regulation of two interferon-induced human Mx proteins. Cell Biol. 9 (1989) 5062-5072
2. Appay V., and Rowland-Jones S.L. RANTES: a versatile and controversial chemokine. Trends Immunol. 22 (2001) 83-87
3. Bagnato F., Durastanti V., Finamore L., Volante G., and Millefiorini E. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis. Neurol. Sci. 24 (2003) 301-304
4. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J.R. Stat. Soc. B 57 (1995) 289-300
5. Chu T.M., et al. A systematic statistical linear modeling approach to oligonucleotide array experiments. Math. Biosci. 176 (2002) 35-51
6. Deisenhammer F., Reindl M., Harvey J., Gasse T., Dilitz E., and Berger T. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 54 (1999) 2055-2060
7. Fernald G.H., Knott S., Pachner A., Caillier S.J., Narayan K., Oksenberg J.R., Mousavi P., and Baranzini S.E. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J. Immunol. 178 (2007) 5076-5085
8. Gilli F., Marnetto F., Stefanuto G., Rinaldi V., Farinazzo F., Malucchi S., Capobianco M., Caldano M., Sala A., and Bertolotto A. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Mol. Diagn. 8 (2004) 185-194
9. Halloran M.C., and Wolman M.A. Repulsion or adhesion: receptors make the call. Curr. Opin. Cell Biol. 18 (2006) 533-540
10. Hoffmann G., Wirleitner B., and Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm. Res. 52 (2003) 313-321
11. Hovanessian A.G., and Justesen J. The human 2′-5′ oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′ instead of 3′-5′ phosphodiester bond formation. Biochimie 89 (2007) 779-788
12. Hubbard T.J., Aken B.L., Beal K., Ballester B., Caccamo M., Chen Y., Clarke L., Coates G., Cunningham F., Cutts T., Down T., Dyer S.C., Fitzgerald S., Fernandez-Banet J., Graf S., Haider S., Hammond M., Herrero J., Holland R., Howe K., Johnson N., Kahari A., Keefe D., Kokocinski F., Kulesha E., Lawson D., Longden I., Melsopp C., Megy K., Meidl P., Ouverdin B., Parker A., Prlic A., Rice S., Rios D., Schuster M., Sealy I., Severin J., Slater G., Smedley D., Spudich G., Trevanion S., Vilella A., Vogel J., White S., Wood M., Cox T., Curwen V., Durbin R., Fernandez-Suarez X.M., Flicek P., Kasprzyk A., Proctor G., Searle S., Smith J., Ureta-Vidal A., and Birney E. Ensembl 2007. Nucleic Acids Res. 35 (2007) 610-617
13. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285
14. Jin R., Bay B.H., Chow V.T., Tan P.H., and Lin V.C. Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. Br. J. Cancer 83 (2000) 319-323
15. Kantor A.B., Deng J., Waubant E., Lin H., Becker C.H., Lacy J.R., Perrone A.M., Bennett D., and Goelz S.E. Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad-based phenotypic profiling. J. Neuroimmunol. 188 (2007) 103-116
16. Kappos L., Polman C.H., Freedman M.S., Edan G., Hartung H.P., Miller D.H., Montalban X., Barkhof F., Bauer L., Jakobs P., Pohl C., and Sandbrink R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67 (2006) 1242-1249
17. Kappos L., Freedman M.S., Polman C.H., Edan G., Hartung H.P., Miller D.H., Montalban X., Barkhof F., Radü E.W., Bauer L., Dahms S., Lanius V., Pohl C., and Sandbrink R. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370 (2007) 389-397
18. Littell, et al. SAS® System for Mixed Models (1996), SAS Institute Inc., Cary, NC
19. Liu W.M., Mei R., Di X., Ryder T.B., Hubbell E., Dee S., Webster T.A., Harrington C.A., Ho M.H., Baid J., and Smeekens S.P. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics 18 (2002) 1593-1599
20. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T))Method. Methods 25 (2001) 402-408
21. Pachner A.R., Bertolotto A., and Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity. Neurology 61 (2003) 24-26
22. Palacios E.H., and Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23 (2004) 7990-8000
23. Penkowa M., and Hidalgo J. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis. J. Neurosci. Res. 72 (2003) 574-586
24. Penkowa M., Espejo C., Martinez-Cáceres E.M., Poulsen C.B., Montalban X., and Hidalgo J. Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. J. Neuroimmunol. 119 (2001) 248-260
25. Rainen L., Oelmueller U., Jurgensen S., Wyrich R., Ballas C., Schram J., Herdman C., Bankaitis-Davis D., Nicholls N., Trollinger D., and Tryon V. Stabilization of mRNA expression on whole blood samples. Clin. Chem. 48 (2002) 1883-1890
26. Riedl S.J., and Salvesen G.S. The apoptosome: signalling platform of cell death. Nat. Rev., Mol. Cell Biol. 8 (2007) 405-413
27. Rani M.R., Shrock J., Appachi S., Rudick R.A., Williams B.R., and Ransohoff R.M. Novel interferon-beta-induced gene expression in peripheral blood cells. J. Leukoc. Biol. 82 (2007) 1353-1360
28. Rivett A.J., and Hearn A.R. Proteasome function in antigen presentation: immunoproteasome complexes, peptide production and interactions with viral proteins. Curr. Protein Pept. Sci. 5 (2004) 153-161
29. Salmon P., Le Cotonnec J.Y., Galazka A., Abdul-Ahad A., and Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J. Interferon Cytokine Res. 16 (1996) 759-764
30. Santos R., Weinstock-Guttman B., Tamãno-Blanco M., Badgett D., Zivadinov R., Justinger T., Munschauer III F., and Ramanathan M. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J. Neuroimmunol. 176 (2006) 125-133
31. SAS Institute Inc. SAS Online Doc®, Version 8 (1999), SAS Institute Inc., Cary, NC
32. Satoh J., Nanri Y., Tabunoki H., and Yamamura T. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis. BMC Neurol. 6 (2006) 18
33. Scagnolari C., Bellomi F., Trombetti S., Casato M., Carlesimo M., Bagnato F., Lavolpe V., Bruno R., Millefiorini E., Antonelli L., Girardi E., Turriziani O., and Antonelli G. Expression of biomarkers of interferon type I in patients suffering from chronic diseases. Clin. Exp. Immunol. 147 (2007) 270-276
34. Scagnolari C., Duda P., Bagnato F., De Vito G., Alberelli A., Lavolpe V., Girardi E., Durastanti V., Trojano M., Kappos L., and Antonelli G. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies". J. Neurol. 254 (2007) 597-604
35. Schall T.J. Biology of the RANTES/SIS cytokine family. Cytokine 3 (1991) 165-183
36. Shin E.C., Seifert U., Kato T., Rice C.M., Feinstone S.M., Kloetzel P.M., and Rehermann B. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J. Clin. Invest. 16 (2006) 3006-3014
37. Singh M.K., Scott T.F., LaFramboise W.A., Hu F.Z., Post J.C., and Ehrlich G.D. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing ß-interferon therapy. J. Neurol. Sci. 258 (2007) 52-59
38. Stankovic R.K., Chung R.S., and Penkowa M. Metallothioneins I and II: neuroprotective significance during CNS pathology". Int. J. Biochem. Cell Biol. 39 (2007) 484-489
39. Stuerzebecher S., Maibauer R., Heunaer A., Beckmann K., and Aufdembrinke B. Pharmacodynamic comparison of single doses of IFN-ß1a and IFN-ß1b in healthy volunteers. J. Interferon Cytokine Res. 19 (1999) 1257-1264
40. Stürzebecher S., Wandinger K.P., Rosenwald A., Sathyamoorthy M., Tzou A., Mattar P., Frank J.A., Staudt L., Martin R., and McFarland H.F. Expression profiling identifies responder and non-responder phenotypes to interferon-ß in multiple sclerosis. Brain 126 (2003) 1419-1429
41. Takaoka A., and Yanai H. Interferon signalling network in innate defence. Cell. Microbiol. 8 (2006) 907-922
42. Ubogu E.E., Callahan M.K., Tucky B.H., and Ransohoff R.M. Determinants of CCL5-driven mononuclear cell migration across the blood-brain barrier. Implications for therapeutically modulating neuroinflammation. J. Neuroimmunol. 179 (2006) 132-144
43. Wandinger K.P., Stürzebecher C.S., Bielekova B., Detore G., Rosenwald A., Staudt L.M., McFarland H.F., and Martin R. Complex immunomodulatory effects of Interferon-beta in multiple sclerosis include the upregulation of T Helper 1-associated marker genes. Ann. Neurol. 50 (2001) 349-357
44. Weinstock-Guttman B., Badgett D., Patrick K., Hartrich L., Santos R., Hall D., Baier M., Feichter J., and Ramanathan M. Genomic effects of IFN-beta in multiple sclerosis patients. J. Immunol. 171 (2003) 2694-2702
45. Williams G.J., and Witt P.L. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J. Interferon Cytokine Res. 18 (1998) 967-975
46. Witt P.L., Storer B.E., Bryan G.T., Brown R.R., Flashner M., Larocca A.T., Colby C.B., and Borden E.C. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. J. Immunother. Emphas. Tumor Immunol. 13 (1993) 191-200